|
|
ACE Inhibitor Intolerance: A major driver of growth for the AIIRBsPublished by: Datamonitor Published: Apr. 30, 2002 - 42 Pages Table of ContentsEXECUTIVE SUMMARY INTRODUCTION OVERVIEW OF DRUG CLASSES Angiotensin converting enzyme (ACE) inhibitors Class overview Approved indications Angiotensin II receptor blockers (AIIRBs) Class overview Approved indications ACE inhibitors versus AIIRBs Global sales of the leading ACE inhibitors and AIIRBs Hypertensive patients receiving ACE inhibitors and AIIRBs Increased use of ACE inhibitors ACE INHIBITOR INTOLERANCE ACE inhibitor intolerance in the seven major markets Hypertensive patients Heart failure patients SPICE - Studies of Patients Intolerant to Converting Enzyme What causes intolerance to ACE inhibitors? Alternative therapy for ACE inhibitor intolerant patients Hypertensive patients Heart failure patients Review of clinical trial data ONTARGET and TRANSCEND - head-to-head trial CASE STUDY ACE inhibitor and AIIRB trends in England Prescription volume Prescription value Cost per prescription Branded enalapril versus generic enalapril Summary APPENDIX Datamonitor's Cardiovascular Business Unit Bibliography Further reading from Datamonitor © Datamonitor 2002. All Rights Reserved. AbstractThis brief explores in detail the impact of generic ACE inhibitors on the AIIRB market, a theme raised in recent Datamonitor reports covering antihypertensive drugs. It is particularly topical, given the recent FDA approval of Sankyo Pharma/Forest Laboratories' new angiotensin II receptor blocker, Benicar (olmesartan) for marketing in the US. The Brief draws together and builds on Treatment Algorithm survey findings in heart failure and hypertension for 7 countries, with epidemiology data, literature search material and a case study based on UK Department of Health prescription audit data for England. The Brief provides: * detailed analysis of the estimated proportion of hypertensive and heart failure patients that are ACE intolerant in the seven major pharmaceutical markets (US, Japan, Germany, France, Italy, Spain, UK) * clinical trial data investigating ACE inhibitor intolerance * a breakdown of the causes of ACE inhibitor intolerance * assessment of alternative therapies for ACE intolerant patients * summary of ACE inhibitor and AIIRB prescription trends in England from 1998 to 2001, and an analysis of the impact of generic enalapril within this market.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||